To test the feasibility of translating recent technological advances in MRSI of prostate cancer at 7T to the regular 3T platform to improve the capacity to separate partially overlapping peaks of polyamines from choline and creatine
ID
Source
Brief title
Condition
- Reproductive neoplasms male malignant and unspecified
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
To show the feasibility of acquiring 1H MRSI in prostate with reduced chemical
shift artifacts at 3T using the FOCI RF pulses in a editing semi-LASER
sequence. Quantification for comparison of the metabolite concentrations will
be obtained with the LC model.
Secondary outcome
N.A
Background summary
Accurate staging of prostate cancer is critical to avoid overtreatment of
low-risk or under treatment of high-risk disease. The Gleason score (GS) is a
highly prognostic measure of tumor differentiation, sampling errors in biopsy
procedures make it hard to identify the most aggressive part of the tissue.
MR spectroscopic imaging (MRSI) has proven its value in the diagnosis of
prostate cancer. It is particularly beneficial where the specificity of other
MRI techniques is poor, such as in the transition zone. However, its use in
clinical practice is limited by a poor sensitivity, partly caused by the
limited spectral resolution available. Limitations in bandwidth (typically in
clinical setups) result in a geometrical mismatch between metabolites.
Polyamines (PA) are one of the metabolites present in the prostate, which can
have a prognostic value of tumor aggressiveness. The PA are located at 3.1 ppm
in the MR spectrum and overlap with creatine (3.0 ppm) and choline (3.2 ppm).
Editing MRS sequences allow the single detection of polyamines without
contamination of other metabolites. We have previously developed an MRSI
sequence with frequency-offset-corrected-inversion (FOCI) pulses at a 7 Tesla
MR scanner to increase the bandwidth up to a factor 10. Therefore, the
geometric mismatch between metabolites is dramatically reduced.
Study objective
To test the feasibility of translating recent technological advances in MRSI of
prostate cancer at 7T to the regular 3T platform to improve the capacity to
separate partially overlapping peaks of polyamines from choline and creatine
Study design
To test the feasibility of translating recent technological advances in MRSI of
prostate cancer at 7T to the regular 3T platform to improve the capacity to
separate partially overlapping peaks of polyamines from choline and creatine.
A group of 10 patients with biopsy-proven prostate cancer scheduled for a
diagnostic MRI exam at 3T with an endorectal coil will be scanned, including
the newly developed FOCI/editing MRSI sequence.
The duration of the study depends on the patients that are willing to
participate in the study. We estimate a maximum duration of half a year.
Intervention
MRSI scan will be extended by 20 minutes
Study burden and risks
MRSI scan will be extended by 20 minutes, which does not involve additional
risk.
Plesmanlaan 121
Amsterdam 1066CX
NL
Plesmanlaan 121
Amsterdam 1066CX
NL
Listed location countries
Age
Inclusion criteria
Patients with biopsy*proven prostate cancer who are eligible for a brachytherapy screening MRI exam of the prostate with an endorectal coil.
Exclusion criteria
• Contra-indications for a MRI exam according to the standard protocol for the screening of patients with prostate cancer
• Treatment of prostate cancer prior to the MRI exams, including hormonal therapy and trans-urethral resection (TURP)
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL48573.031.14 |